Teacher Retirement System of Texas Has $14.61 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teacher Retirement System of Texas increased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 38.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 662,797 shares of the company's stock after buying an additional 184,915 shares during the quarter. Teacher Retirement System of Texas owned about 0.06% of Teva Pharmaceutical Industries worth $14,608,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in TEVA. Diversify Advisory Services LLC grew its stake in shares of Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after purchasing an additional 496 shares in the last quarter. Sanctuary Advisors LLC grew its position in Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock valued at $601,000 after buying an additional 664 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in Teva Pharmaceutical Industries by 0.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after buying an additional 699 shares during the period. Metis Global Partners LLC raised its position in shares of Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after buying an additional 860 shares in the last quarter. Finally, DGS Capital Management LLC lifted its stake in shares of Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock worth $246,000 after acquiring an additional 872 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

A number of research firms recently commented on TEVA. Bank of America lowered their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th. Piper Sandler boosted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Finally, Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Trading Down 2.0 %

Shares of NYSE:TEVA traded down $0.33 during midday trading on Tuesday, reaching $15.86. The company had a trading volume of 2,244,489 shares, compared to its average volume of 9,436,029. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80. The firm has a market cap of $17.98 billion, a price-to-earnings ratio of -10.93, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a fifty day simple moving average of $17.70 and a two-hundred day simple moving average of $18.19.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.